Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Nanomedicine and Nanosensors in Cancer Therapies
share announcement

Nanomedicine and Nanosensors in Cancer Therapies

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (25 February 2023) | Viewed by 5728

Special Issue Editors

Dr. Milena Trevisan Pelegrino

E-Mail Website1 Website2
Guest Editor
Institute of Environmental, Chemical and Pharmaceutical Sciences (ICAQF), Federal University of São Paulo (UNIFESP), São Paulo, Brazil
Interests: polymer; cancer; nitric oxide; nanomaterials
Prof. Dr. Amedea B. Seabra

E-Mail Website
Guest Editor
Center for Natural and Human Sciences (CCNH), Federal University of ABC (UFABC), Av. dos Estados, 5001-Bangú, Santo André 09210-580, SP, Brazil
Interests: nanomaterials; biomaterials; drug delivery; nitric oxide; cytotoxicity
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Nanomedicine focuses on the effect of nanomaterials in biological systems to achieve a more efficient therapy or increase the accuracy of diagnosis. Cancer is a leading cause of death worldwide. Nanotechnology studies have, thus far, showed successful results for cancer therapy and diagnosis. Nanomedicine can be classified as a material with at least one nanometric component, which can include metallic nanoparticles, polymeric nanoparticles, graphene and others.

This Special Issue aims to shed light on the current state of the art of nanomedicine in cancer therapy. We invite articles on all aspects of drug targeting, pharmacokinetics and pharmacodynamics. Manuscripts regarding issues such as multiple-drug resistance tumors and a combination of nanomaterials and chemotherapy and radiotherapy agents will be highlighted.

Dr. Milena Trevisan Pelegrino
Prof. Dr. Amedea B. Seabra
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer treatment
  • nanosensor
  • nanoparticle
  • nanomedicine
  • target drug
  • pharmacokinetics
  • pharmacodynamics

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

19 pages, 5822 KiB  
Article
Pluronic F-127 Hydrogels Containing Copper Oxide Nanoparticles and a Nitric Oxide Donor to Treat Skin Cancer
by Fernanda V. Cabral, Bianca de Melo Santana, Camila N. Lange, Bruno L. Batista, Amedea B. Seabra and Martha S. Ribeiro
Pharmaceutics 2023, 15(7), 1971; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics15071971 - 18 Jul 2023
Cited by 5 | Viewed by 1463
Abstract
Melanoma is a serious and aggressive type of skin cancer with growing incidence, and it is the leading cause of death among those affected by this disease. Although surgical resection has been employed as a first-line treatment for the early stages of the [...] Read more.
Melanoma is a serious and aggressive type of skin cancer with growing incidence, and it is the leading cause of death among those affected by this disease. Although surgical resection has been employed as a first-line treatment for the early stages of the tumor, noninvasive topical treatments might represent an alternative option. However, they can be irritating to the skin and result in undesirable side effects. In this context, the potential of topical polymeric hydrogels has been investigated for biomedical applications to overcome current limitations. Due to their biocompatible properties, hydrogels have been considered ideal candidates to improve local therapy and promote wound repair. Moreover, drug combinations incorporated into the polymeric-based matrix have emerged as a promising approach to improve the efficacy of cancer therapy, making them suitable vehicles for drug delivery. In this work, we demonstrate the synthesis and characterization of Pluronic F-127 hydrogels (PL) containing the nitric oxide donor S-nitrosoglutathione (GSNO) and copper oxide nanoparticles (CuO NPs) against melanoma cells. Individually applied NO donor or metallic oxide nanoparticles have been widely explored against various types of cancer with encouraging results. This is the first report to assess the potential and possible underlying mechanisms of action of PL containing both NO donor and CuO NPs toward cancer cells. We found that PL + GSNO + CuO NPs significantly reduced cell viability and greatly increased the levels of reactive oxygen species. In addition, this novel platform had a huge impact on different organelles, thus triggering cell death by inducing nuclear changes, a loss of mitochondrial membrane potential, and lipid peroxidation. Thus, GSNO and CuO NPs incorporated into PL hydrogels might find important applications in the treatment of skin cancer. Full article
(This article belongs to the Special Issue Nanomedicine and Nanosensors in Cancer Therapies)
►▼ Show Figures

Figure 1

16 pages, 5797 KiB  
Article
Cytotoxicity towards Breast Cancer Cells of Pluronic F-127/Hyaluronic Acid Hydrogel Containing Nitric Oxide Donor and Silica Nanoparticles Loaded with Cisplatin
by Bianca de Melo Santana, Joana Claudio Pieretti, Rafael Nunes Gomes, Giselle Cerchiaro and Amedea Barozzi Seabra
Pharmaceutics 2022, 14(12), 2837; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics14122837 - 17 Dec 2022
Cited by 7 | Viewed by 2066
Abstract
The incorporation of both nitric oxide (NO) donor (S-nitrosoglutathione, GSNO) and silica nanoparticles loaded with cisplatin (SiO2@CisPt NPs) into a polymeric matrix represents a suitable approach to creating a drug-delivery system with sustained and localized drug release against tumor cells. Herein, [...] Read more.
The incorporation of both nitric oxide (NO) donor (S-nitrosoglutathione, GSNO) and silica nanoparticles loaded with cisplatin (SiO2@CisPt NPs) into a polymeric matrix represents a suitable approach to creating a drug-delivery system with sustained and localized drug release against tumor cells. Herein, we report the synthesis, characterization, and cytotoxicity evaluation of Pluronic F-127/hyaluronic acid hydrogel containing GSNO and SiO2@CisPt NPs against breast cancer cells. SiO2@CisPt NPs were successfully synthesized, revealing a spherical morphology with an average size of 158 ± 20 nm. Both GSNO and SiO2@CisPt NPs were incorporated into the thermoresponsive Pluronic/hyaluronic hydrogel for sustained and localized release of both NO and cisplatin. The kinetics of NO release from a hydrogel matrix revealed spontaneous and sustained release of NO at the millimolar range for 24 h. The MTT assay showed concentration-dependent cytotoxicity of the hydrogel. The combination of GSNO and SiO2@CisPt incorporated into a polymeric matrix decreased the cell viability 20% more than the hydrogel containing only GSNO or SiO2@CisPt. At 200 µg/mL, this combination led to a critical cell viability of 30%, indicating a synergistic effect between GSNO and SiO2@CisPt NPs in the hydrogel matrix, and, therefore, highlighting the potential application of this drug-delivery system in the field of biomedicine. Full article
(This article belongs to the Special Issue Nanomedicine and Nanosensors in Cancer Therapies)
►▼ Show Figures

Graphical abstract

15 pages, 3347 KiB  
Article
Magnetite Microspheres for the Controlled Release of Rosmarinic Acid
by Cristina Chircov, Diana-Cristina Pîrvulescu, Alexandra Cătălina Bîrcă, Ecaterina Andronescu and Alexandru Mihai Grumezescu
Pharmaceutics 2022, 14(11), 2292; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics14112292 - 26 Oct 2022
Cited by 5 | Viewed by 1522
Abstract
Since cancer incidence is constantly increasing, novel and more efficient treatment methods that overcome the current limitations of chemotherapy are continuously explored. In this context, the aim of the present study was to investigate the potential of two types of magnetite microspheres as [...] Read more.
Since cancer incidence is constantly increasing, novel and more efficient treatment methods that overcome the current limitations of chemotherapy are continuously explored. In this context, the aim of the present study was to investigate the potential of two types of magnetite microspheres as drug delivery vehicles for the controlled release of rosmarinic acid (RA) in anticancer therapies. The magnetite microspheres were obtained through the solvothermal method by using polyethylene glycol (PEG) with two different molecular weights as the surfactant. The physicochemical characterization of the so-obtained drug delivery carriers involved X-ray diffraction (XRD) coupled with Rietveld refinement, scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FT-IR), dynamic light scattering (DLS) and zeta potential, and UV–Vis spectrophotometry. The magnetite-based anticancer agents were biologically evaluated through the ROS-Glo H2O2 and MTT assays. Results proved the formation of magnetite spheres with submicronic sizes and the effective RA loading and controlled release, while the biological assays demonstrated the anticancer potential of the present systems. Thus, this study successfully developed a promising drug delivery alternative based on magnetite that could be used in the continuous fight against cancer. Full article
(This article belongs to the Special Issue Nanomedicine and Nanosensors in Cancer Therapies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop